Cancer Treatment Reviews
Volume 28, Issue 6 , Pages 321-333 , December 2002

Management of the menopause in cancer survivors

  • Mark Clemons

      Affiliations

    • Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ont., Canada M4N 3M5
    • Corresponding Author InformationCorrespondence to: Mark Clemons, Division of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ont., Canada M4N 3M5. Tel.: +416-480-5847; Fax: +416-217-1338
    • ,
  • Andrew Clamp

      Affiliations

    • Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK
    • ,
  • Beverley Anderson

      Affiliations

    • Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK

References 

  1. Feldman BM, Voda A, Gronseth E. The prevalence of hot flash and associated variables among perimenopausal women. Res. Nurs. Health. 1985;8:261–268
  2. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J. Clin. Oncol. 1996;14:1718–1729
  3. Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J. Clin. Oncol. 1999;17:2365–2370
  4. Clark ST, Radford JA, Crowther D, Swindell R, Shalet SM. Gonadal function following chemotherapy for Hodgkins disease: a comparative study of MVPP and a seven-drug hybrid regimen. J. Clin. Oncol. 1995;13:134–139
  5. Byrne J, Fears TR, Gail MH, Pee D, Connelly RR, Austin DF, et al. Early menopause in long-term survivors of cancer during adolescence. Am. J. Obstet. Gynecol. 1992;166:788–793
  6. Hopwood P. Living with advanced breast cancer: development and application of a clinical checklist for patients on endocrine therapy. The Breast. 1998;7:14–21
  7. Kronenberg F. Hot flashes: phenomenology, quality of life, and search for treatment options. Exp. Gerontol. 1994;29:319–336
  8. Bachman GA. Vasomotor flushes in menopausal women. Am. J. Obstet. Gynecol. 1999;180:S312–S316
  9. Lamb MA. Effects of cancer on the sexuality and fertility of women. Semin. Oncol. Nurs. 1995;11:120–127
  10. Finck G, Barton DL, Loprinzi CL, Quella SK, Sloan JA. Definitions of hot flashes in breast cancer survivors. J. Pain Symptom Manage. 1998;16:327–333
  11. Nesheim BI, Saetre T. Reduction of menopausal hot flushes by methyldopa. A double blind crossover trial. Eur. J. Clin. Pharmacol. 1981;20:413–416
  12. Casper RF, Yen SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin. Endocrinol. 1985;22:293–312
  13. Bider D, Mashiach S, Serr DM, Ben-Rafael Z. Endocrinological basis of hot flushes. Obstet. Gynecol. Surv. 1989;44:495–499
  14. McKinlay SM, Jefferys M. The menopausal syndrome. Br. J. Prev. Soc. Med. 1974;28:108–115
  15. Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M. Measuring the impact of menopausal symptoms on quality of life. BMJ. 1993;307:836–840
  16. Ganz PA, Rowland JH, Meyerowitz BE, Desmond KA. Impact of different adjuvant therapy strategies on quality of life in breast cancer survivors. Recent Results Cancer Res. 1998;152:396–411
  17. Couzi RJ, Helzlsouer KJ, Fetting JH. Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J. Clin. Oncol. 1995;13:2737–2744
  18. Meyerowitz BE, Desmond KA, Rowland JH, Wyatt GE, Ganz PA. Sexuality following breast cancer. J. Sex Marital Ther. 1999;25:237–250
  19. Carpenter JS. Hot flashes and their management in breast cancer. Semin. Oncol. Nurs. 2000;16:214–225
  20. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al. Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J. Clin. Oncol. 1998;16:994–999
  21. Stein KD, Jacobsen PB, Hann DM, Greenberg H, Lyman G. Impact of hot flashes on quality of life among postmenopausal women being treated for breast cancer. J. Pain Symptom Manage. 2000;19:436–445
  22. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, et al  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N. Engl. J. Med. 1989;320:479–484
  23. Love RR, Camern L, Connell BL, et al.  Symptoms associated with tamoxifen treatment in postmenopausal women. Arch. Intern. Med. 1991;151:1842–1847
  24. Loprinzi CL, Zahasky KM, Sloan JA, et al.  Tamoxifen-induced hot flashes. Clin. Breast Cancer. 2000;1:52–56
  25. Bergmans MG, Merkus JM, Corbey RS, Schellekens LA, Ubachs JM. Effect of Bellergal Retard on climacteric complaints: a double-blind, placebo-controlled study. Maturitas. 1987;9:227–234
  26. Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J. Natl. Cancer Inst. 2000;92:1054–1064
  27. Germaine LM, Freedman RR. Behavioral treatment of menopausal hot flashes: evaluation by objective methods. J. Consult. Clin. Psychol. 1984;52:1072–1079
  28. Freedman RR, Woodward S. Behavioral treatment of menopausal hot flushes: evaluation by ambulatory monitoring. Am. J. Obstet. Gynecol. 1992;167:436–439
  29. Irvin JH, Domar AD, Clark C, Zuttermeister PC, Friedman R. The effects of relaxation response training on menopausal symptoms. J. Psycho. Obstet. Gynecol. 1996;17:202–207
  30. Towlerton G, Filshie J, O’Brien M, Duncan A. Acupuncture in the control of vasomotor symptoms caused by tamoxifen. Palliat. Med. 1999;13:445
  31. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet. Gynecol. 1994;83:12–18
  32. Clemons M, Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 2001;344:276–285
  33. Ganz PA, Greendale GA, Kahn B, O’Leary JF, Desmond KA. Are older breast carcinoma survivors willing to take hormone replacement therapy?. Cancer. 1999;86:814–820
  34. Baum M. Hormone replacement therapy and breast cancer. Lancet. 1994;343:53
  35. Baum M. The control of acute menopausal symptoms in breast cancer survivors. Ann. Oncol. 2000;11:9
  36. Eden JA, Bush T, Nand S. A case-control study of combined continuous oestrogen–progestin replacement therapy among women with a personal history of breast cancer. Menopause. 1995;2:67–72
  37. Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, et al. Oestrogen replacement therapy after localized breast cancer: clinical outcome of 319 women followed prospectively. J. Clin. Oncol. 1999;17:1482–1487
  38. Loprinzi CL, Barton D. Oestrogen deficiency: in search of symptom control and sexuality. J. Natl. Cancer Inst. 2000;92:1028–1029
  39. O’Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J. Natl. Cancer Inst. 2001;93:754–762
  40. Vassilopoulou-Sellin R, Zolinski C. Estrogen replacement therapy in women with breast cancer: a survey of patient attitudes. Am. J. Med. Sci. 1992;304:145–149
  41. Swain S, Santen R, Burger H, Pritchard K. Treatment of estrogen deficiency symptoms in women surviving breast cancer. Part 6: Executive summary and consensus statement. Proceedings of a conference held at the Boar’s Head Inn, Charlottesville, Virginia. September 21–23, 1997. Oncology 1999; 13: 1–8
  42. Vassilopoulou-Sellin R, Theriault RL. Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. J. Natl. Cancer Inst. Monogr. 1994;16:153–159
  43. Marsden J, Whitehead M, A’Hern R, Baum M, Sacks N. Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?. Fertil. Steril. 2000;73:292–299
  44. Pritchard KI, Khan H, Levine M. Clinical Practice Guidelines for the care and treatment of breast cancer: 14 The role of hormone replacement therapy in women with a previous diagnosis of breast cancer. CMAJ. 2002;166:1017–1022
  45. Erlik Y, Meldrum DR, Lagasse LD, Judd HL. Effect of megestrol acetate on flushing and bone metabolism in post-menopausal women. Maturitas. 1981;3:167–172
  46. Albrecht BH, Schiff I, Tulchinsky D, Ryan KJ. Objective evidence that placebo and oral medroxyprogesterone acetate therapy diminish menopausal vasomotor flushes. Am. J. Obstet. Gynecol. 1981;139:631–635
  47. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, et al. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998;82:1784–1788
  48. Loprinzi CL, Michalak JC, Quella SK, O’Fallon JR, Hatfield AK, Nelimark RA, et al  Megestrol acetate for the prevention of hot flashes. N. Engl. J. Med. 1994;331:347–352
  49. Bullock JL, Massey FM, Gambrell RD. Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet. Gynecol. 1975;46:165–168
  50. Bertelli G, Venturini M, DelMastro L, et al.  Depot intramuscular medroxyprogesterone acetate (MAP) vs oral megesterol acetate (MA) for the treatment of hot flashes in breast cancer survivors: results of GONO (Gruppo Oncologico Nord Ovest) MIG-4 phase III trial. Proc. Am. Soc. Clin. Oncol. 1999;18: abstr 592
  51. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J. Steroid Biochem. Mol. Biol. 2001;76:231–238
  52. Rymer J, Morris EP. Menopausal symptoms. BMJ. 2001;321:1516–1519
  53. Roux C, Pelissier C, Fechtenbaum J, Loiseau-Peres S, Benhamou CL. Randomized double-masked, 2-year comparison of tibolone with 17β-estradiol and norethindrone acetate in preventing postmenopausal bone loss. Osteoporos. Int. 2002;13:241–248
  54. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomised, double-blind, placebo-controlled, dose-finding studies. J. Clin. Endocrinol. Metab. 2001;86:4717–4726
  55. Lippert C, Seeger H, Wallwiener D, Mueck AO. Tibolone versus 17β-estradiol/norethisterone: effects on the proliferation of human breast cancer cells. Eur. J. Gynecol. Oncol. 2002;23:127–130
  56. Kloosterboer HJ, Schoonen WGEJ, Deckers GH, Klijn JGM. Effect of progestagens and Org OD14 in in vitro and in vivo tumor models. J. Steroid Biochem. Mol. Biol. 1994;49:311–318
  57. Colacurci N, Mele D, De Franciscis P, Costa V, Fortunato N, De Seta D. Effects of tibolone on the breast. Eur. J. Obstet. Gynecol. Reprod. Biol. 1998;80:235–238
  58. Lundstrom E, Christow A, Kersemaekers W, Sbane G, Azavedo E, Solderqvist G, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am. J. Obstet. Gynecol. 2002;186:717–722
  59. Pansini F, Albertazzi P, Bonaccorsi G, Zanotti L, Porto S, Dossi L, et al. Trazodone: a non-hormonal alternative for neurovegetative climacteric symptoms. Clin. Exp. Obstet. Gynecol. 1995;22:341–344
  60. Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, et al. A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. Ann. Oncol. 2000;11:17–22
  61. Plouffe L, Trott EA, Largoza M, Hansen KA. An open trial of sertraline for menopausal hot flushes: potential involvement of serotonin in vasomotor instability. Del. Med. J. 1997;69:481–482
  62. Roth AJ, Scher HI. Sertraline relieves hot flashes secondary to medical castration as treatment of advanced prostate cancer. Psychooncology. 1998;7:129–132
  63. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J. Clin. Oncol. 2002;20:1578–1583
  64. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, et al. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J. Urol. 1999;162:98–102
  65. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet. 2000;356:2059–2063
  66. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double-blind trial of a non-hormonal medication. Br. Med. J. 1974;1:409–412
  67. Edington RF, Chagnon JP, Steinberg WM. Clonidine (Dixarit) for menopausal flushing. Can. Med. Assoc. J. 1980;123:23–26
  68. Laufer LR, Erlik Y, Meldrum DR, Judd HL. Effect of clonidine on hot flashes in postmenopausal women. Obstet. Gynecol. 1982;60:583–586
  69. Wren BG, Brown LB. A double-blind trial with clonidine and a placebo to treat hot flushes. Med. J. Aust. 1986;144:369–370
  70. Loprinzi CL, Goldberg RM, O’Fallon JR, Quella SK, Misek AW, Mynderse LA, et al. Transdermal clonidine for ameliorating postorchiectomy hot flashes. J. Urol. 1993;151:634–636
  71. Goldberg RM, Loprinzi CL, O’Fallon JR, Veeder MH, Miser AW, Mailliard JA, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J. Clin. Oncol. 1994;12:155–158
  72. Pandya KJ, Loughner J, Raubertas R, Bennett JM. A double blind placebo controlled trial of clonidine for vasomotor symptoms in breast cancer patients on tamoxifen. Proc. Am. Soc. Clin. Oncol. 1990;9:340
  73. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann. Intern. Med. 2000;132:788–793
  74. Oddens BJ. The climacteric cross-culturally: the International Health Foundation South-east Asia study. Maturitas. 1994;19:155–156
  75. Tham DM, Gardner CD, Haskell WL. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J. Clin. Endocrinol. Metab. 1998;83:2223–2235
  76. Murkies AL, Lombard C, Strauss BJ, Wilcox G, Burger HG, Morton MS. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas. 1995;21:189–195
  77. Murkies AL, Teede HJ, Davis SR. What is the role of phytoestrogens in treating menopausal symptoms?. Med. J. Aust. 2000;173:S97–S98
  78. Albertazzi P, Pansini F, Bonaccorsi G, Zanotti L, Forini E, De Aloysio D. The effect of dietary soy supplementation on hot flushes. Obstet. Gynecol. 1998;91:6–11
  79. Upmalis DH, Rogerio L, Bradley L, Warren M, Cone FL, Lamia CA. Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomised, placebo-controlled study. Menopause. 2000;7:236–242
  80. Consensus Opinion from The Board of Trustees of NAMS. The role of isoflavones in menopausal health: consensus opinion of the North American Menopause Society. Menopause 2000; 7: 215–229
  81. Fugh-Berman A, Kronenberg F. Red clover (Trifolium pratense) for menopausal women: current state of knowledge. Menopause. 2001;8:333–337
  82. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause. 2001;8:259–265
  83. Van Patten CVL, Olivotto IA, Chambers K, Gelman KA, Hislop G, Templeton E, et al. Effect of soy phytoestrogen on hot flashes in postmenopausal women with breast cancer: a randomized controlled clinical trial. J. Clin. Oncol. 2002;20:1449–1455
  84. Ginsburg J, Prelevic GM. Lack of significant hormonal effects and controlled trials of phyto-estrogens. Lancet. 2000;355:163–164
  85. Hale GE, Hughes CL, Robboy SJ, Agarwal SK, Bievre M. A double-blind randomized study on the effects of red clover isoflavones on the endometrium. Menopause. 2001;8:338–346
  86. Christy C. Vitamin E in menopause. Am. J. Obstet. Gynecol. 1945;50:84–87
  87. Finkler RS. The effect of vitamin E in the menopause. J. Clin. Endocrinol. Metab. 1949;9:89–94
  88. McLaren H. Vitamin E in menopause. BMJ. 1949;2:1378–1381
  89. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 1998;90:1371–1388
  90. Barton DL, Loprinzi CL, Quella SK, Sloan JA, Veeder MH, Egner JR, et al. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J. Clin. Oncol. 1998;16:495–500
  91. Coope J, Williams S, Patterson JS. A study of the effectiveness of propranolol in menopausal hot flushes. Br. J. Obstet. Gynaecol. 1978;85:472–475
  92. Chenoy R, Hussain S, Tayob Y, O’Brien PM, Moss MY, Morse PF. Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. BMJ. 1994;308:501–503
  93. Jacobson JS, Troxel AB, Evans J, Klaus L, Vahdat L, Kinne D, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J. Clin. Oncol. 2001;19:2739–2745
  94. Hammon MG, Hatley L, Talbert LM. A double blind study to evaluate the effect of methyldopa on menopausal vasomotor flushes. J. Clin. Endocrinol. Metab. 1984;58:1158–1160
  95. Andersen O, Engebretsen T, Solberg VM, Orbo A. α-Methyldopa for climacteric hot flushes. A double-blind, randomized, cross-over study. Acta Obstet. Gynecol. Scand. 1986;65:405–409
  96. Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome. Gynecology. 1969;33:795–799
  97. Guttuso T. Gabapentin’s effects on hot flashes and hypothermia. Neurology. 2000;54:2161–2163
  98. Loprinzi CL, Barton DL, Rhodes D. Management of hot flashes in breast-cancer survivors. Lancet Oncol. 2001;2:199–204
  99. Bachmann GA. The clinical platform for the17β-estradiol vaginal releasing ring. Am. J. Obstet. Gynecol. 1998;178:S257–S260
  100. Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Clin. Oncol. 1999;17:2659–2669
  101. Nachtigall LE. Comparative study: Replens versus local estrogen in menopausal women. Fertil. Steril. 1994;61:178–180
  102. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, vanHaelst-Pisani C, Hammer AM, Rowland KM, et al. Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J. Clin. Oncol. 1997;15:969–973
  103. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am. J. Obstet. Gynecol. 1999;180:1072–1079
  104. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. Br. J. Obst. Gynecol. 2000;107:1029–1034
  105. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur. J. Obstet. Gynecol. Reprod. Biol. 1997;71:73–80
  106. Gabrielsson J, Wallenbeck I, Birgerson L. Pharmacokinetic data on estradiol in light of the estring concept. Estradiol and estring pharmacokinetics. Acta Obstet. Gynecol. Scand. Suppl. 1996;163:26–31
  107. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ. 1999;319:630–635
  108. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. NEJM. 1995;333:1301–1307
  109. The LIPID group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol. NEJM 1998; 339: 1349–1357
  110. Darling GM, Jowns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. NEJM. 1997;337:595–601
  111. Davidson MH, Testolin LM, Maki KC, von Duillard S, Drennan KB. A comparison of estrogen replacement, pravastatin and combined treatment for the management of hypercholesterolemia in postmenopausal women. Arch. Intern. Med. 1997;157:1186–1192
  112. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605–613
  113. Mosea L, Collins P, Herrington DM, Mendelsohn ME, Pasternak RC, Robertson RM, et al. Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2001;104:499–503
  114. Womens Health Initiative Investigators Writing Group. Risks and benefits of estrogen and progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333
  115. Bilimoria MM, Jordan VC, Morrow M. Additional benefits of tamoxifen for postmenopausal patients. In:  Jordan VC editors. Tamoxifen: a guide for clinicians and patients. Huntington, NY: PRR; 1996;p. 75–89
  116. Osborne CK. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 1998;339:1609–1618
  117. Love RR, Wiebe DA, Feyzi JM, Newcomb PA, Chappell RJ. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. J. Natl. Cancer Inst. 1996;86:1534–1539
  118. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451–1467
  119. Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG. American Society of Clinical Oncology technology assessment of breast cancer risk reduction strategies: tamoxifen and raloxifene. J. Clin. Oncol. 1999;17:1939–1955
  120. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifeneon bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 1997;337:1641–1647
  121. Khovidhunkit W, Shoback DM. Clinical effects of raloxifene hydrochloride in women. Ann. Intern. Med. 1999;130:431–439
  122. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998;279:1445–1451
  123. Jordan VC, Morrow M. Raloxifene as a multifunctional medicine? Current trials will show whether it is effective in both osteoporosis and breast cancer. BMJ. 1999;319:331–332
  124. Barrett-Connor E, Grady D, Sashegyi A, Andreson PW, Cox DA, Hoszowski K, et al. Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four year results from the MORE (Multiple Outcomes of Raloxifene) randomized trial. JAMA. 2002;287:847–857
  125. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J. Clin. Oncol. 1997;15:1341–1347
  126. Burstein HJ, Winer EP. Primary care for survivors of breast cancer. N. Engl. J. Med. 2000;343:1086–1094
  127. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 1997;337:670–676
  128. Lufkin EG, Wahner HW, O’Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann. Intern. Med. 1992;117:1–9
  129. Schneider DI, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernando Study. JAMA. 1997;277:543–547
  130. Hosking D, Chilvers CE, Christiansen C, Ravn P, Wasnich R, Ross P. Prevention of bone loss with alendronate in postmenopausal women under 60 years of age – Early Postmenopausal Intervention Cohort Study Group. N. Engl. J. Med. 1998;338:485–492
  131. Powles TJ, McCloskey E, Paterson AH, Ashley S, Tidy VA, Nevantaus A, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J. Natl. Cancer Inst. 1998;90:704–708
  132. Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 2002;346:653–661
  133. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC. Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res. Treat. 1988;12:297–302
  134. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J. Clin. Oncol. 1996;14:78–84
  135. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. JAMA. 1999;282:637–645
  136. Resnick SM, Metter EJ, Zonderman AB. Estrogen replacement therapy and longitudinal decline in visual memory.A possible protective effect?. Neurology. 1997;49:1491–1497
  137. Matthews K, Cauley J, Yaffe K, Zmuda JM. Estrogen replacement therapy and cognitive decline in older community women. J. Am. Geriatr. Soc. 2000;48:345–346
  138. Polo-Kantola P, Portin R, Polo O, Helenius H, Irjala K, Erkkola R. The effect of short-term estrogen replacement therapy on cognition: A randomized double-blind, cross-over trial in postmenopausal women. Obstet. Gynecol. 1998;91:459–466
  139. Sherwin BB. Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinol. 1988;13:345–347
  140. Kampen DL, Sherwin BB. Estrogen use and verbal memory in healthy postmenopausal women. Obstet. Gynecol. 1994;83:979–983
  141. Yaffe K, Krueger K, Sarkar S, Grady D, Barrett-Connor E, Cox DA, et al. Cognitive function in postmenopausal women treated with raloxifene. N. Engl. J. Med. 2001;344:1207–1213
  142. Radford JA, Lieberman BA, Brison DR, Smith AR, Critchlow JD, Ryssell SA, et al. Othotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkins lymphoma. Lancet. 2001;357:1172–1175
  143. Oktay K, Economos K, Kan M, Rucinski J, Veeck L, Rosenwaks Z. Endocrine function and oocyte retrieval after autologous transplantation of ovarian cortical strips to the forearm. JAMA. 2001;286:1490–1493

PII: S0305-7372(02)00089-0

Cancer Treatment Reviews
Volume 28, Issue 6 , Pages 321-333 , December 2002

Article Tools

* Image Usage & Resolution